» Articles » PMID: 29488056

Effect of Achieving Sustained Virological Response Before Hepatitis C Virus-related Hepatocellular Carcinoma Occurrence on Survival and Recurrence After Curative Surgical Microwave Ablation

Overview
Journal Hepatol Int
Publisher Springer
Specialty Gastroenterology
Date 2018 Mar 1
PMID 29488056
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aim: The effects of achieving sustained virological response (SVR) on recurrence and survival after curative treatment in patients with hepatitis virus C (HCV)-related hepatocellular carcinoma (HCC) is unclear. This study examined the influence of SVR achievement by interferon therapy before HCC occurrence on recurrence and survival.

Methods: This retrospective study included 518 patients who underwent surgical microwave ablation for initial HCV-related HCC between January 2001 and December 2015. Thirty-four patients had achieved SVR (SVR group) and 484 patients had not (control group). Clinical characteristics and long-term outcomes were compared between the two groups.

Results: Overall survival rates at 5 and 10 years after curative ablation were 95.8 and 80.4% in the SVR group, and 50.7 and 23.4% in the control, respectively (p < 0.0001). Recurrence-free survival rates at 5 and 10 years were 68.7 and 26.4% in the SVR group, and 24.5 and 7.8% in the control group, respectively (p < 0.0001). Multivariate analyses revealed that achieving SVR as an independent prognostic factor for both overall and recurrence-free survival. In the SVR group, the 5-year recurrence-free survival rates for patients with an interval of 5 years or fewer (n = 24) vs. more than 5 years (n = 10) between achieving SVR and curative ablation were 58.7 and 88.9%, respectively (p = 0.03).

Conclusions: Achieving SVR before HCC occurrence allowed a favorable clinical outcome after curative ablation in HCV-related HCC patients. Patients with HCC that occurred more than 5 years after achieving SVR had longer recurrence-free survival.

Citing Articles

Impact of DAA Treatment for HCV on Hepatocellular Carcinoma in a Predominately African American Population.

Itani M, Farah B, Wasvary M, Wadehra A, Wilson T, Rutledge B J Gastrointest Cancer. 2024; 55(3):1324-1332.

PMID: 38972941 DOI: 10.1007/s12029-024-01076-w.


Consensus on the tertiary prevention of primary liver cancer.

Nan Y, Xu X, Dong S, Yang M, Li L, Zhao S Hepatol Int. 2023; 17(5):1057-1071.

PMID: 37369911 PMC: 10522749. DOI: 10.1007/s12072-023-10549-2.


Effects of Achieving SVR on Clinical Characteristics and Surgical Outcomes in Patients Who Developed Early-Stage HCV-Related Hepatocellular Carcinoma and Received Curative Resection: Preoperative versus Postoperative SVR.

Hsu P, Liang P, Huang C, Hsieh M, Tsai Y, Lin T Viruses. 2022; 14(11).

PMID: 36366510 PMC: 9693099. DOI: 10.3390/v14112412.


Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival.

Sun Y, Zhang H, Long J, Zhang Y, Zheng J, Yuan C Front Oncol. 2022; 12:978614.

PMID: 36212462 PMC: 9539218. DOI: 10.3389/fonc.2022.978614.


Nomogram based on albumin-bilirubin grade to predict outcome of the patients with hepatitis C virus-related hepatocellular carcinoma after microwave ablation.

An C, Li X, Yu X, Cheng Z, Han Z, Liu F Cancer Biol Med. 2020; 16(4):797-810.

PMID: 31908896 PMC: 6936230. DOI: 10.20892/j.issn.2095-3941.2018.0486.


References
1.
Saito T, Chiba T, Suzuki E, Shinozaki M, Goto N, Kanogawa N . Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Med Sci. 2014; 11(7):707-12. PMC: 4025170. DOI: 10.7150/ijms.8764. View

2.
Llovet J, Schwartz M, Mazzaferro V . Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005; 25(2):181-200. DOI: 10.1055/s-2005-871198. View

3.
. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet. 1999; 351(9115):1535-9. View

4.
Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M . Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999; 29(4):1124-30. DOI: 10.1002/hep.510290439. View

5.
Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View